FDA OKs anti-wrinkle drug, long-lasting Botox competitor Revance Therapeutics Inc Food and Drug Administration NASD 2022

FDA OKs anti-wrinkle drug, long-lasting Botox competitor The day the Food and Drug Administration (FDA) thoroughly

 approved the anti-wrinkle injection Daxify, competition for Botox has been established, dominating the market for two decades.

Manufacturer Ravance Therapeutics said its study shows the drug can temporarily improve moderate to severe

frown lines for about six months, twice the duration of Botox. Daxxify will greatly expand its own reach in the $3.2 billion

facial injectable market, the company said in a statement. Ravens said Daxxify Safe was well tolerated,

 with no serious treatment-related adverse events reported in clinical trials. The drug achieved clinically

 significant improvement with long-lasting results, high patient satisfaction. Of the more than 2,700 patients studied,

98 percent had no mild wrinkles four weeks after the injection. The effects lasted up to six months, 

with some patients seeing results for up to nine months. Like Botox, Daxxify is a neuromuscular blocking agent. Similar

 to other products, the FDA warns its effects may spread to other areas of the body. The FDA warned 

about the potential for general muscle weakness or difficulty breathing with the use of toxin-based treatments; 

the most common side effects with Daxxify were headache, eyelid ptosis, in which the upper eyelid droops over the eye.

Ravens did not disclose the price of the injections, she noted significant advances in the field of facial injectable drugs in 30 years.

Ravens said it plans to roll out Daxxify to high-volume injectors in the US, with an initial training

FDA education program at the company headquarters in Nashville, followed by a wider commercial launch.